Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Recruiting1
Completed1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

recruiting133%
completed133%
suspended133%

Recent Activity

1 active trials
Showing 3 of 3
completedphase_3

Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

NCT04839354
recruiting

Association Between Postoperative Administration of L-Arginine and CSA-AKI

NCT06248359
suspendedphase_2

Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria

NCT00616304

Clinical Trials (3)

Showing 3 of 3 trials
NCT04839354Phase 3

Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

Completed
NCT06248359

Association Between Postoperative Administration of L-Arginine and CSA-AKI

Recruiting
NCT00616304Phase 2

Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria

Suspended

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3